The global pharmaceutical portfolio today reflects a greater prevalence of large molecule drugs, expansion in the number of personalized products, and a rise in orphan disease treatments. Over 1,000 biologics have been approved worldwide and more than 8,000 are in development to help address unmet healthcare needs.
To meet therapy production demands, the industry needs to have the right capacity, in the right locations. Increasingly, single-use technologies are being seen as the solution to flexibly and cost-effectively address many of the challenges around creating biologics manufacturing capacity. And it’s the fastest way to bring capacity online.